Bionovate Supports Startups in the Digital Health Markets

Rhea-AI Summary

Bionovate Technologies Corp (OTCMKT: BIIO) is actively seeking investments in digital healthcare start-ups, spurred by the COVID-19 pandemic's acceleration of the sector. The company highlights the increasing patient engagement and rising smartphone usage as key market drivers. Bionovate also considers taking promising start-ups public via SPACs, leveraging its expertise in navigating capital acquisition without traditional IPO restrictions. The focus remains on building an ecosystem of mobile health services aimed at chronic disease management, especially utilizing IoT and AI technologies.

Positive

• Exploration of investments in digital healthcare start-ups could yield significant growth opportunities.
• Potential for taking start-ups public via SPACs, easing capital acquisition.
• Emphasis on digital transformation aligns with increasing patient engagement in healthcare.

Negative

• Dependence on third-party suppliers and partners poses risks to operational execution.
• Potential delays and quality issues associated with outsourced components could affect timelines.
• Regulatory changes and geopolitical factors may impact business strategy.

CHAM, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp (OTCMKT: BIIO) (“Bionovate”), is currently in the process of compiling a shortlist for potential investments in start-ups in the digital healthcare markets, as announced. The COVID-19 pandemic has accelerated the digital transformation of the healthcare market and launched numerous innovative start-ups.

One of the key drivers is the growing willingness of patients to participate in managing their own diseases and improving their lifestyles. Major pharmaceutical companies, payers and insurance companies have now recognized the business benefits of patient engagement and are investing heavily in mobile applications. Rising smartphone penetration and integration of advanced technologies, such as the Internet of Things (IoT) and artificial intelligence (AI), and increasing implementation of mHealth technologies for self-management of chronic diseases, such as diabetes, are some of the key factors driving the market. Moreover, the hardware segment and sensor market is also driven by the latest technological advancements in manufacturing techniques and miniaturization.

Bionovate is also looking at the possibility of taking promising startups public via SPACs. Bionovate has a lot of experience and brings together the partners needed for such a transaction. The startup has the advantage of accessing fresh capital without having to comply with the strict rules of a normal IPO.

About Bionovate Technologies Corp.
Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an ecosystem of medical devices and mobile applications to turn health care data into personal digital services with a great user experience on mobile devices. Innovations in this field are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide.

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham
Switzerland

Press contact:
Sandra Meyer
Tel: +41 581 01 02 02
Mail: press@bionovate.com 

 

FAQ

What investment strategy is Bionovate Technologies Corp (BIIO) pursuing?

Bionovate is focusing on investing in start-ups within the digital healthcare markets.

How has the COVID-19 pandemic influenced Bionovate's business decisions?

The pandemic has accelerated the digital transformation of the healthcare sector, prompting Bionovate to seek new investments.

What are some key factors driving the digital healthcare market according to Bionovate?

Key factors include increased patient engagement, smartphone penetration, and advancements in IoT and AI technologies.

Is Bionovate considering SPACs for its investment strategy?

Yes, Bionovate is looking to take promising start-ups public via SPACs, leveraging its experience in the process.

What challenges could affect Bionovate's business strategy?

Challenges include dependency on suppliers, regulatory changes, and potential delays in component production.